[go: up one dir, main page]

AR076113A1 - Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento - Google Patents

Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento

Info

Publication number
AR076113A1
AR076113A1 ARP100100765A ARP100100765A AR076113A1 AR 076113 A1 AR076113 A1 AR 076113A1 AR P100100765 A ARP100100765 A AR P100100765A AR P100100765 A ARP100100765 A AR P100100765A AR 076113 A1 AR076113 A1 AR 076113A1
Authority
AR
Argentina
Prior art keywords
treatment
methyl
follow
indolinone
methylcarbonyl
Prior art date
Application number
ARP100100765A
Other languages
English (en)
Inventor
Kazuhiko Nakagawa
Tokuzo Arao
Kanae Kudo
Nishio Kazuto
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076113(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR076113A1 publication Critical patent/AR076113A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se provee además un kit diagnostico y el uso de un biomarcador para hacer el seguimiento del compuesto 3-Z-[1-(4-(N-((4-metil-piperazin-1-iI)-metilcarbonil)-N-metil amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona o una sal farmacéuticamente aceptable del mismo. Reivindicacion 1: Un método o sistema para el seguimiento del tratamiento de un individuo con el compuesto 3-Z-[1-(4-(N-((4-metil-piperazin-1-iI)-metilcarbonil)-N-metil amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona o una sal farmacéuticamente aceptable del mismo, caracterizado porque comprende determinar si una muestra de dicho individuo comprende un biomarcador en una cantidad que es indicativa para dicho tratamiento.
ARP100100765A 2009-03-12 2010-03-11 Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento AR076113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12

Publications (1)

Publication Number Publication Date
AR076113A1 true AR076113A1 (es) 2011-05-18

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100765A AR076113A1 (es) 2009-03-12 2010-03-11 Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento

Country Status (24)

Country Link
US (1) US8802384B2 (es)
EP (1) EP2406628A1 (es)
JP (1) JP5667581B2 (es)
KR (1) KR20110137307A (es)
CN (1) CN102334030A (es)
AR (1) AR076113A1 (es)
AU (1) AU2010223256B2 (es)
BR (1) BRPI1011688A2 (es)
CA (1) CA2755055A1 (es)
CL (1) CL2011002260A1 (es)
CO (1) CO6430497A2 (es)
EA (1) EA201101300A1 (es)
EC (1) ECSP11011323A (es)
IL (1) IL214747A0 (es)
MA (1) MA33120B1 (es)
MX (1) MX2011009482A (es)
NZ (1) NZ594843A (es)
PE (1) PE20120592A1 (es)
SG (1) SG174324A1 (es)
TN (1) TN2011000457A1 (es)
TW (1) TW201100802A (es)
UA (1) UA107789C2 (es)
UY (1) UY32482A (es)
WO (1) WO2010103058A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20100254A1 (es) * 2008-06-06 2010-04-21 Boehringer Ingelheim Int Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
CA3172586C (en) 2013-07-31 2025-10-14 Avalyn Pharma Inc. IMATINIB AEROSOL COMPOUNDS AND RELATED USES
US11397178B2 (en) 2016-10-28 2022-07-26 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
ATE475884T1 (de) 2006-04-18 2010-08-15 Wellstat Biologics Corp Detektion von zirkulierenden endothelzellen
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
JP2010502209A (ja) * 2006-09-07 2010-01-28 アストラゼネカ アクチボラグ Ｒｅｔレセプターチロシンキナーゼを標的とする薬剤による治療のために患者を評価する方法
US20100234381A1 (en) 2007-04-13 2010-09-16 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
WO2008134526A2 (en) 2007-04-27 2008-11-06 University Of Florida Research Foundation Inc. Glycoprotein profiling of bladder cancer

Also Published As

Publication number Publication date
MX2011009482A (es) 2011-09-27
JP2012520446A (ja) 2012-09-06
ECSP11011323A (es) 2011-10-31
US8802384B2 (en) 2014-08-12
TN2011000457A1 (en) 2013-03-27
WO2010103058A1 (en) 2010-09-16
AU2010223256B2 (en) 2014-08-21
PE20120592A1 (es) 2012-06-09
EA201101300A1 (ru) 2012-04-30
BRPI1011688A2 (pt) 2016-03-22
AU2010223256A1 (en) 2011-09-15
IL214747A0 (en) 2011-11-30
SG174324A1 (en) 2011-10-28
CA2755055A1 (en) 2010-09-16
JP5667581B2 (ja) 2015-02-12
UA107789C2 (en) 2015-02-25
MA33120B1 (fr) 2012-03-01
CO6430497A2 (es) 2012-04-30
TW201100802A (en) 2011-01-01
NZ594843A (en) 2014-03-28
US20100233705A1 (en) 2010-09-16
EP2406628A1 (en) 2012-01-18
CL2011002260A1 (es) 2012-03-23
KR20110137307A (ko) 2011-12-22
UY32482A (es) 2010-10-29
CN102334030A (zh) 2012-01-25

Similar Documents

Publication Publication Date Title
AR076113A1 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
CU24058B1 (es) Antagonistas de pcsk9
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
CL2007003793A1 (es) Metodo para inhibir union del receptor de muerte 6 (dr6) a la proteina precursora amiloide (app) que comprende uno o mas antagonistas del dr6; uso de dichos antagonistas; metodo para identificar una molecula de interes que inhibe la union del dr6 a l
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
CO6680668A2 (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
EP2061907A4 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
MX355416B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
EA201490832A1 (ru) Биомаркеры, имеющие прогностическое значение в отношении ответа на лечение активатором альфа 7 никотиновых ацетилхолиновых рецепторов
NI200900081U (es) Anticuerpos agonistas de trkb y sus usos.
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
WO2011143574A3 (en) Plasma biomarkers for diagnosis of alzheimer's disease
EA201171178A1 (ru) Устройство и способ для определения и количественного анализа аналитов, в частности, микотоксинов
CL2011002973A1 (es) Metodo para detectar anticuerpos en una muestra que comprende contactar una muestra con un soporte que tiene fijado un peptoide; kit para detectar anticuerpos que son indicativos de una enfermedad neurodegenerativa.
BR112015019567A8 (pt) inibidor de wnt, seu uso e métodos para prognosticar sensibilidade ao mesmo, e composição farmacêutica
ES2640752T3 (es) Agonistas del receptor 5-HT4 para el tratamiento de la demencia
PE20080908A1 (es) Agonistas lxr para el tratamiento de osteoartritis
WO2011130647A3 (en) Compositions and methods for characterizing a myopathy
MX2021009281A (es) Metodos de deteccion de legionella.
CY1121482T1 (el) Ευαισθητη πολυπλεκτικη ανοσοδοκιμασια για τους διαλυτους υποδοχεις των αυξητικων παραγοντων των ινοβλαστων

Legal Events

Date Code Title Description
FB Suspension of granting procedure